| Baseline characteristics (n= 794) . | Centre A (n= 284) . | Centre B (n= 176) . | Centre C (n= 127) . | Centre D (n= 207) . | P value . |
|---|---|---|---|---|---|
| Male | 242 (85%) | 137 (78%) | 68 (54%) | 147 (71%) | <0.001 |
| Age (year) | 64 ± 10 | 70 ± 9 | 70 ± 10 | 64 ± 11 | <0.001 |
| Prevalence of ischaemic cardiomyopathy | 156 (55%) | 104 (59%) | 61 (48%) | 113 (55%) | 0.301 |
| History of revascularization in ischaemic patients | 43 (15%) | 32 (18%) | 51 (40%) | 33 (16%) | <0.001 |
| Severity of MR at baseline | |||||
| No MR | 29 (10%) | 17 (10%) | 17 (13%) | 47 (23%) | <0.001 |
| Mild–moderate MR | 103 (36%) | 129 (73%) | 73 (58%) | 104 (50%) | <0.001 |
| Advanced MR | 152 (54%) | 30 (17%) | 37 (29%) | 56 (27%) | <0.001 |
| NYHA class | 3.01 ± .52 | 3.09 ± 0.49 | 2.87 ± 0.50 | 2.97 ± 0.47 | 0.002 |
| QRS duration (ms) | 178 ± 28 | 142 ± 31 | 154 ± 30 | 166 ± 32 | <0.001 |
| LVEDD (mm/m) | 74 ± 9 | 68 ± 9 | 66 ± 9 | 65 ± 11 | <0.002 |
| LVESD (mm/m) | 65 ± 7 | 57 ± 9 | 56 ± 9 | 55 ± 13 | 0.133 |
| LVEF (%) | 22 ± 4 | 27 ± 6 | 28 ± 8 | 22 ± 9 | <0.001 |
| Prevalence of RV dilatation | 68 (24%) | 124 (71%) | 11 (9%) | 29 (14%) | <0.001 |
| Follow-up | |||||
| Change in MR | |||||
| MR improvement ≥1° | 69 (24%) | 50 (28%) | 30 (24%) | 73 (35%) | <0.001 |
| No change in MR | 59 (21%) | 76 (43%) | 30 (24%) | 67 (32%) | <0.001 |
| MR worsening ≥1° | 28 (10%) | 17 (10%) | 4 (3%) | 43 (21%) | <0.001 |
| MR from FU not available | 128 (45%) | 33 (19%) | 63 (50%) | 24 (12%) | <0.001 |
| NYHA | 2.42 ± 0.6 | 2.39 ± 0.81 | 2.53 ± 0.60 | 2.25 ± 0.63 | 0.008 |
| LVEDD (mm/m) | 72 ± 10 | 65 ± 9 | 64 ± 11 | 63 ± 12 | <0.001 |
| LVESD (mm/m) | 63 ± 12 | 53 ± 11 | 52 ± 13 | 51 ± 14 | 0.212 |
| LVEF (%) | 25 ± 8 | 33 ± 11 | 39 ± 13 | 26 ± 12 | <0.001 |
| Baseline characteristics (n= 794) . | Centre A (n= 284) . | Centre B (n= 176) . | Centre C (n= 127) . | Centre D (n= 207) . | P value . |
|---|---|---|---|---|---|
| Male | 242 (85%) | 137 (78%) | 68 (54%) | 147 (71%) | <0.001 |
| Age (year) | 64 ± 10 | 70 ± 9 | 70 ± 10 | 64 ± 11 | <0.001 |
| Prevalence of ischaemic cardiomyopathy | 156 (55%) | 104 (59%) | 61 (48%) | 113 (55%) | 0.301 |
| History of revascularization in ischaemic patients | 43 (15%) | 32 (18%) | 51 (40%) | 33 (16%) | <0.001 |
| Severity of MR at baseline | |||||
| No MR | 29 (10%) | 17 (10%) | 17 (13%) | 47 (23%) | <0.001 |
| Mild–moderate MR | 103 (36%) | 129 (73%) | 73 (58%) | 104 (50%) | <0.001 |
| Advanced MR | 152 (54%) | 30 (17%) | 37 (29%) | 56 (27%) | <0.001 |
| NYHA class | 3.01 ± .52 | 3.09 ± 0.49 | 2.87 ± 0.50 | 2.97 ± 0.47 | 0.002 |
| QRS duration (ms) | 178 ± 28 | 142 ± 31 | 154 ± 30 | 166 ± 32 | <0.001 |
| LVEDD (mm/m) | 74 ± 9 | 68 ± 9 | 66 ± 9 | 65 ± 11 | <0.002 |
| LVESD (mm/m) | 65 ± 7 | 57 ± 9 | 56 ± 9 | 55 ± 13 | 0.133 |
| LVEF (%) | 22 ± 4 | 27 ± 6 | 28 ± 8 | 22 ± 9 | <0.001 |
| Prevalence of RV dilatation | 68 (24%) | 124 (71%) | 11 (9%) | 29 (14%) | <0.001 |
| Follow-up | |||||
| Change in MR | |||||
| MR improvement ≥1° | 69 (24%) | 50 (28%) | 30 (24%) | 73 (35%) | <0.001 |
| No change in MR | 59 (21%) | 76 (43%) | 30 (24%) | 67 (32%) | <0.001 |
| MR worsening ≥1° | 28 (10%) | 17 (10%) | 4 (3%) | 43 (21%) | <0.001 |
| MR from FU not available | 128 (45%) | 33 (19%) | 63 (50%) | 24 (12%) | <0.001 |
| NYHA | 2.42 ± 0.6 | 2.39 ± 0.81 | 2.53 ± 0.60 | 2.25 ± 0.63 | 0.008 |
| LVEDD (mm/m) | 72 ± 10 | 65 ± 9 | 64 ± 11 | 63 ± 12 | <0.001 |
| LVESD (mm/m) | 63 ± 12 | 53 ± 11 | 52 ± 13 | 51 ± 14 | 0.212 |
| LVEF (%) | 25 ± 8 | 33 ± 11 | 39 ± 13 | 26 ± 12 | <0.001 |
MR, mitral regurgitation; NYHA, New York Heart Association; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; RV, right ventricular; FU, follow-up.
| Baseline characteristics (n= 794) . | Centre A (n= 284) . | Centre B (n= 176) . | Centre C (n= 127) . | Centre D (n= 207) . | P value . |
|---|---|---|---|---|---|
| Male | 242 (85%) | 137 (78%) | 68 (54%) | 147 (71%) | <0.001 |
| Age (year) | 64 ± 10 | 70 ± 9 | 70 ± 10 | 64 ± 11 | <0.001 |
| Prevalence of ischaemic cardiomyopathy | 156 (55%) | 104 (59%) | 61 (48%) | 113 (55%) | 0.301 |
| History of revascularization in ischaemic patients | 43 (15%) | 32 (18%) | 51 (40%) | 33 (16%) | <0.001 |
| Severity of MR at baseline | |||||
| No MR | 29 (10%) | 17 (10%) | 17 (13%) | 47 (23%) | <0.001 |
| Mild–moderate MR | 103 (36%) | 129 (73%) | 73 (58%) | 104 (50%) | <0.001 |
| Advanced MR | 152 (54%) | 30 (17%) | 37 (29%) | 56 (27%) | <0.001 |
| NYHA class | 3.01 ± .52 | 3.09 ± 0.49 | 2.87 ± 0.50 | 2.97 ± 0.47 | 0.002 |
| QRS duration (ms) | 178 ± 28 | 142 ± 31 | 154 ± 30 | 166 ± 32 | <0.001 |
| LVEDD (mm/m) | 74 ± 9 | 68 ± 9 | 66 ± 9 | 65 ± 11 | <0.002 |
| LVESD (mm/m) | 65 ± 7 | 57 ± 9 | 56 ± 9 | 55 ± 13 | 0.133 |
| LVEF (%) | 22 ± 4 | 27 ± 6 | 28 ± 8 | 22 ± 9 | <0.001 |
| Prevalence of RV dilatation | 68 (24%) | 124 (71%) | 11 (9%) | 29 (14%) | <0.001 |
| Follow-up | |||||
| Change in MR | |||||
| MR improvement ≥1° | 69 (24%) | 50 (28%) | 30 (24%) | 73 (35%) | <0.001 |
| No change in MR | 59 (21%) | 76 (43%) | 30 (24%) | 67 (32%) | <0.001 |
| MR worsening ≥1° | 28 (10%) | 17 (10%) | 4 (3%) | 43 (21%) | <0.001 |
| MR from FU not available | 128 (45%) | 33 (19%) | 63 (50%) | 24 (12%) | <0.001 |
| NYHA | 2.42 ± 0.6 | 2.39 ± 0.81 | 2.53 ± 0.60 | 2.25 ± 0.63 | 0.008 |
| LVEDD (mm/m) | 72 ± 10 | 65 ± 9 | 64 ± 11 | 63 ± 12 | <0.001 |
| LVESD (mm/m) | 63 ± 12 | 53 ± 11 | 52 ± 13 | 51 ± 14 | 0.212 |
| LVEF (%) | 25 ± 8 | 33 ± 11 | 39 ± 13 | 26 ± 12 | <0.001 |
| Baseline characteristics (n= 794) . | Centre A (n= 284) . | Centre B (n= 176) . | Centre C (n= 127) . | Centre D (n= 207) . | P value . |
|---|---|---|---|---|---|
| Male | 242 (85%) | 137 (78%) | 68 (54%) | 147 (71%) | <0.001 |
| Age (year) | 64 ± 10 | 70 ± 9 | 70 ± 10 | 64 ± 11 | <0.001 |
| Prevalence of ischaemic cardiomyopathy | 156 (55%) | 104 (59%) | 61 (48%) | 113 (55%) | 0.301 |
| History of revascularization in ischaemic patients | 43 (15%) | 32 (18%) | 51 (40%) | 33 (16%) | <0.001 |
| Severity of MR at baseline | |||||
| No MR | 29 (10%) | 17 (10%) | 17 (13%) | 47 (23%) | <0.001 |
| Mild–moderate MR | 103 (36%) | 129 (73%) | 73 (58%) | 104 (50%) | <0.001 |
| Advanced MR | 152 (54%) | 30 (17%) | 37 (29%) | 56 (27%) | <0.001 |
| NYHA class | 3.01 ± .52 | 3.09 ± 0.49 | 2.87 ± 0.50 | 2.97 ± 0.47 | 0.002 |
| QRS duration (ms) | 178 ± 28 | 142 ± 31 | 154 ± 30 | 166 ± 32 | <0.001 |
| LVEDD (mm/m) | 74 ± 9 | 68 ± 9 | 66 ± 9 | 65 ± 11 | <0.002 |
| LVESD (mm/m) | 65 ± 7 | 57 ± 9 | 56 ± 9 | 55 ± 13 | 0.133 |
| LVEF (%) | 22 ± 4 | 27 ± 6 | 28 ± 8 | 22 ± 9 | <0.001 |
| Prevalence of RV dilatation | 68 (24%) | 124 (71%) | 11 (9%) | 29 (14%) | <0.001 |
| Follow-up | |||||
| Change in MR | |||||
| MR improvement ≥1° | 69 (24%) | 50 (28%) | 30 (24%) | 73 (35%) | <0.001 |
| No change in MR | 59 (21%) | 76 (43%) | 30 (24%) | 67 (32%) | <0.001 |
| MR worsening ≥1° | 28 (10%) | 17 (10%) | 4 (3%) | 43 (21%) | <0.001 |
| MR from FU not available | 128 (45%) | 33 (19%) | 63 (50%) | 24 (12%) | <0.001 |
| NYHA | 2.42 ± 0.6 | 2.39 ± 0.81 | 2.53 ± 0.60 | 2.25 ± 0.63 | 0.008 |
| LVEDD (mm/m) | 72 ± 10 | 65 ± 9 | 64 ± 11 | 63 ± 12 | <0.001 |
| LVESD (mm/m) | 63 ± 12 | 53 ± 11 | 52 ± 13 | 51 ± 14 | 0.212 |
| LVEF (%) | 25 ± 8 | 33 ± 11 | 39 ± 13 | 26 ± 12 | <0.001 |
MR, mitral regurgitation; NYHA, New York Heart Association; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; RV, right ventricular; FU, follow-up.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
